Drug Trial Radar · NCT06754891
Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
Last checked: Nov 20, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
135
Planned (sponsor's estimate)
Start
Jan 28, 2025
Primary completion
Jul 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase will commence following dose escalation in the 24mg bid group during Phase I. Employing a 1:1:1 randomized, double-blind, placebo-controlled study design, it will evaluate the efficacy, safety, and Pharmacokinetics/Pharmacodynamics (PK/PD) characteristics of TQH3906 capsules in subjects with moderate-to-severe active ulcerative colitis. The study will include a maximum 4-week screening period, a 12-week treatment period, and a 4-week post-treatment follow-up period, enrolling a total of 105 subjects. Among these, subjects who failed conventional therapy and those who failed biologic therapy each constitute 35% of the cohort. week treatment period, and a 4-week post-treatment follow-up period. A total of 105 subjects will be enrolled, with 50% comprising subjects who failed conventional therapy and 50% comprising subjects who failed biologic therapy. Dose Group Design: Group A: Placebo Group B: 32mg dose group Group C: 24mg bid dose group The specific dose will be determined based on the 48mg dose group's medication experience from Phase I and adjusted as necessary.
Conditions
- Inflammatory Bowel Diseases
Interventions
24mg bid TQH3906 capsuleDrug
TQH3906 is an allosteric inhibitor targeting kinase developed by Chia Tai Tianqing Pharmaceutical Co., Ltd.
32mg TQH3906 capsuleDrug
TQH3906 is an allosteric inhibitor targeting kinase developed by Chia Tai Tianqing Pharmaceutical Co., Ltd.
TQH3906 placeboDrug
TQH3906 is an allosteric inhibitor targeting kinase developed by Chia Tai Tianqing Pharmaceutical Co., Ltd.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse event rateTime frame: Baseline up to week 16
- Clinical remission rate: Ulcerative colitis (UC): Mayo scoreTime frame: Week 8
- Clinical remission rate: Ulcerative colitis (UC): Crohn's disease (CD)Time frame: Week 8
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
The First Affilliated Hospital of Bengbu Medical University
Bengbu, Anhui, China · Not yet recruiting
Gansu Wuwei Tumour Hospital
Wuwei, Gansu, China · Not yet recruiting
First affiliated hospital of guangzhou medical university
Guangzhou, Guangdong, China · Not yet recruiting
Zhujiang Hospital, of Southern Medical University
Guangzhou, Guangdong, China · Not yet recruiting
Huizhou First People's Hospital
Huizhou, Guangdong, China · Not yet recruiting
Heilongjiang provincial hospital
Harbin, Heilongjiang, China · Not yet recruiting
Luoyang Central Hospital (Zhengzhou University Affiliated Luoyang Central Hospital)
Luoyang, Henan, China · Not yet recruiting
Luoyang First People's Hospital
Luoyang, Henan, China · Not yet recruiting
Nanyang Second General Hospital
Nanyang, Henan, China · Not yet recruiting
Henan Provincial People's Hospital
Zhengzhou, Henan, China · Not yet recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Not yet recruiting
The Second Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Not yet recruiting
Union Hosiptal, Tongji Medical College, Huazhong University of Science And Technolocy
Wuhan, Hubei, China · Not yet recruiting
Renmin Hospital of Wuhan University
Wuhan, Hubei, China · Not yet recruiting
Hunan Provincial People's Hospital
Changsha, Hunan, China · Not yet recruiting
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China · Not yet recruiting
Xiangya Hospital of Central South University
Changsha, Hunan, China · Not yet recruiting
The First Affiliated Hospital Of University Of South China
Hengyang, Hunan, China · Not yet recruiting
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China · Not yet recruiting
The first hospital of Jilin University
Changchun, Jilin, China · Not yet recruiting
Meihekou Central Hospital
Meihekou, Jilin, China · Not yet recruiting
Shengjing Hospital oh China Medical University
Shenyang, Liaoning, China · Not yet recruiting
The Second School of Clinical Medicine of Shandong First Medical University
Taishan, Shandong, China · Not yet recruiting
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China · Not yet recruiting
Shanxi Provincial People's Hospital
Taiyuan, Shanxi, China · Not yet recruiting
The TCM Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China · Recruiting
Tianjin People's Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China · Recruiting
The First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China · Not yet recruiting
Taizhou Municipal Hospital
Taizhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.